Vitreomacular traction hinders the effectiveness of anti-VEGF therapy in a patient with exudative age-related macular degeneration.
To report a case of exudative age-related macular degeneration (AMD) complicated by vitreomacular traction and treated with intravitreal bevacizumab. Interventional case report. An 83-year-old man presented with exudative AMD with subretinal fluid. Optical coherence tomography (OCT) revealed vitreomacular traction in the left eye. The visual acuity was 20/200. Two monthly intravitreal injections of bevacizumab into the eye were performed; after the vitreomacular traction was resolved, another series of bevacizumab injections were given. After the first 2 injections of bevacizumab, OCT indicated that the macular appearance was unchanged, and visual acuity was reduced to 20/250. The second series of injections resolved the submacular exudation and vision improved to 20/160. In this case, the presence of vitreomacular traction seemed to hinder resolution of submacular exudation after intravitreal injection of bevacizumab. The role of the vitreomacular interface in the effectiveness of antivascular endothelial growth factor therapy in exudative AMD should be considered.